FindTrial
Sign In

Adjunctive dTMS for treatment of negative symptoms in Schizophrenia

Adjunctive Deep Transcranial Magnetic Stimulation (dTMS) for treatment of negative symptoms in schizophrenia A randomised sham controlled h-MRS study - dTMS MRS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/035267
Enrollment
40
Registered
2021-07-29
Start date
Unknown
Completion date
Unknown
Last updated
2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F20- Schizophrenia

Interventions

Intervention1: Deep Transcranial Magnetic Stimulation (dTMS), Active: The helmet with H7 dTMS coil will be placed on the head of the patient. It will be adjusted such that, the maximal stimulation is

Sponsors

Central Institute of Psychiatry
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosis of Schizophrenia using Diagnostic Criteria for Research (DCR) of International Classification of Disease-10th edition (ICD-10, World Health Organization, 1992). 2. Age between 18- 60 years of either sex. 3. Illness duration of equal to or more than 2 years. 4. The Positive and Negative Syndrome Scale for Schizophrenia (PANSS) negative symptoms score of more than 15. 5. Scale for Assessment of Negative Symptoms (SANS) score more than 20. 6. Calgary Depression Scale for Schizophrenia (CDSS) score less than 7. 7. Right-handed. 8. Patients giving written informed consent.

Exclusion criteria

Exclusion criteria: 1. Presence of co-morbid neurological or other psychiatric disorder(s). 2. Patient with co morbid substance dependence, except nicotine and caffeine. 3. Having any metallic implants/parts in body.8 4. Subjects who have received ECT in past 6 months.

Design outcomes

Primary

MeasureTime frame
Primary outcome of this study is the change in negative symptoms score as assessed at the end of 2 weeks of dTMS treatment.Timepoint: Primary outcome of this study is the change in negative symptoms score as assessed at the end of 2 weeks of dTMS treatment.—

Secondary

MeasureTime frame
Secondary outcomes are changes in the levels of GABA, Glutamate, Glutamine, N-Acetyl Aspartate & N-Acetyl Aspartyl Glutamate in Medial Prefrontal Cortex and Anterior Cingulate Cortex using Proton MR Spectroscopic imaging and overall severity scores on CGI.Timepoint: Secondary outcomes are changes in the levels of GABA, Glutamate, Glutamine, N-Acetyl Aspartate & N-Acetyl Aspartyl Glutamate in Medial Prefrontal Cortex and Anterior Cingulate Cortex using Proton MR Spectroscopic imaging and overall severity scores on CGI, will be assessed at end of 2 weeks of dTMS treatment.—

Countries

India

Contacts

Public ContactDr Aniruddha Mukherjee

Central Institute of Psychiatry

Nishantgoyal.cip@gov.in9431171162

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026